Note: This article does not constitute any investment opinions or recommendations; please refer to official/company announcements for accuracy. This article only provides an introduction to medical and health-related drugs, not a recommendation of treatment plans (if involved), and does not represent the platform's position.Any article reprinted needs to be authorized.
On January 13, 2026, SANEGENEBIO announced that its self-developed small interfering RNA (siRNA) candidate drug, SGB-7342, completed the first dosing of a subject in a Phase 1 clinical trial in China for the treatment of obesity at the First Hospital of Jilin University. This randomized, double-blind, placebo-controlled, single ascending dose Phase 1 clinical study aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SGB-7342 in overweight and obese patients.SGB-7342 is an siRNA candidate drug targeting inhibin βE subunit (INHBE) for the treatment of obesity.Developed using SANEGENEBIO's proprietary GalNAc conjugation delivery technology and chemical modification technology. This platform technology has demonstrated potential best-in-class characteristics in Phase 1 clinical trials of multiple siRNA drug candidates under development by the company.SGB-7342 specifically silences the expression of the INHBE gene through RNAi technology, thereby reducing the level of its encoded protein Activin E and effectively inhibiting downstream signaling pathways related to lipid metabolism and energy expenditure. Preclinical studies have shown that SGB-7342 can potently and durably silence INHBE expression, significantly reduce body weight and fat mass while preserving muscle mass, and demonstrate good safety and tolerability.Dr. Jin Yuyan, Senior Vice President of Clinical and Non-clinical at SANEGENEBIO, stated: "The completion of the first subject dosing for SGB-7342 marks a significant milestone in the drug's development process. Based on the RNAi mechanism of action, it has the potential to achieve effective weight loss while avoiding muscle loss, offering an entirely new differentiated treatment strategy for obesity. This progress also represents a solid step forward in SANEGENEBIO’s strategic layout for innovative therapies in obesity and metabolic diseases. We will fully advance the subsequent clinical research of SGB-7342, striving to bring transformative therapies to obese patients worldwide as soon as possible."Source: SANEGENEBIO
Mastering CAR-T Therapy, Stem Cell Therapy, and Gene
Therapy,Comprehensive Information on Oncolytic Viruses and Nucleic Acid Drugs
